Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Nov 21;75(1):161–171. doi: 10.1007/s00280-014-2626-2

Fig. 3.

Fig. 3

t-CUPM exhibits similar caspase-dependent apoptosis to sorafenib. Dose response effects of sorafenib and t-CUPM on HepG2 (a) and Huh-7 (b) cell viability and caspase 3/7 induction. Data for cell viability (MTT assay) and caspase 3/7 induction (luminescence) were determined after a 72-h incubation period for each compound